Diabetic retinopathy: pathogenesis, clinical grading, management and future developments
Top Cited Papers
- 19 May 2013
- journal article
- review article
- Published by Wiley in Diabetic Medicine
- Vol. 30 (6), 640-650
- https://doi.org/10.1111/dme.12089
Abstract
Decades of research into the pathophysiology and management of diabetic retinopathy have revolutionized our understanding of the disease process. Diabetic retinopathy is now more accurately defined as a neurovascular rather than a microvascular disease as neurodegenerative disease precedes and coexists with microvascular changes. However, the complexities of the pathways involved in different stages of disease severity continue to remain a challenging issue for drug discovery. Currently, laser photocoagulation is the mainstay of treatment for proliferative diabetic retinopathy, but is gradually being superseded for diabetic macular oedema. However, it is destructive and at best results in a gradual but modest improvement in vision in the long term. So, diabetic retinopathy remains the most prevalent cause of visual impairment in the working-age population despite established screening programmes, early diagnosis and treatment of the condition. The recent discovery of inhibitors of vascular endothelial growth factor is revolutionizing the management of diabetic retinopathy, particularly diabetic macular oedema. However, not all patients respond to anti-vascular endothelial growth factor agents, reinforcing the fact that diabetic retinopathy is a multifactorial disease. Studies are still required to improve our understanding of how retinal structure correlates with visual function. It is hoped that these will lead to better characterization of the disease phenotype based on treatment responses to different agents and allow an algorithm to be developed that will guide the management of diabetic retinopathy and diabetic macular oedema at different stages of severity.Keywords
This publication has 41 references indexed in Scilit:
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular EdemaArchives of Ophthalmology (1950), 2012
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- FACTORS ASSOCIATED WITH VISUAL ACUITY OUTCOMES AFTER VITRECTOMY FOR DIABETIC MACULAR EDEMARetina, 2010
- Effects of Medical Therapies on Retinopathy Progression in Type 2 DiabetesNew England Journal of Medicine, 2010
- Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive casesBritish Journal of Ophthalmology, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- Three-Year Follow-up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular EdemaArchives of Ophthalmology (1950), 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialThe Lancet, 2008